ACCESSIBILITY

24/7

Headlines

11:58

TSMC proposes Intel foundry takeover, seeks Nvidia, AMD, and Broadcom as partners

10:00

Israel’s mental health tech sector sees surge in investment and innovation

08:46

"Israel is not only on the AI train—but it is sitting in the front cars"

08:40

"Entrepreneurs underestimate how important chemistry is in an acquisition"

Buzz

Most popular

Daily

Weekly

Sola Security aims to be the Wix of cyber with $30 million Seed round

XTEND raises $20 million Series A for drone operating system

"Eventually, AI will surpass us in everything"—so what skills will still matter?

Cybereason secures $120 million investment amid leadership shakeup and abandoned merger

AI startup D-ID lays off a quarter of its workforce just days after Microsoft deal

More news

Kåre Schultz

9 stories about Kåre Schultz

Teva Announces Restructuring, Ousts Second in Command

27.11.17|Golan Hazani

The troubled Israeli drugmaker has combined its generic and specialty drug divisions, effective immediately

Israeli Parliamentarians to Push Against Teva Layoffs in the Country

26.11.17|Dror Reich and Maayan Manela

Shelly Yachimovich, a member of the Israeli parliament representing the Israeli Labor Party, said she intends to call an emergency hearing of the Israeli parliament’s state control committee on the issue. The planned layoffs are a result of the company’s management failures, she added

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani

Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17|Dror Reich and Lilach Baumer

Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich

Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer

The generic drugmaker shed 67% of its market price over the last 12 months

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17|Golan Hazani

Mr. Schultz, who led Copenhagen-based H. Lundbeck A/S since 2015, will come to Israel and assume his new position by the end of the month

The Ten Challenges Facing Teva's New CEO

12.09.17|Sophie Shulman

Kåre Schultz is the right man for the job, but he's facing multiple problems, from a changing market to a problematic board

Teva Appoints Lundbeck's Schultz as CEO

11.09.17|Dror Reich and Micky Grunfeld

The company’s announcement brings an end to a seven month search for a CEO to lead the troubled generic drugmaker. Updated